How to buy Checkmate Pharmaceuticals stock (CMPI)

Checkmate Pharmaceuticals is a biotechnology business based in the US. Checkmate Pharmaceuticals shares (CMPI) are listed on the NASDAQ and all prices are listed in US Dollars. Checkmate Pharmaceuticals employs 30 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Checkmate Pharmaceuticals stock

Buy Checkmate Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Checkmate Pharmaceuticals stock price (NASDAQ: CMPI)

Use our graph to track the performance of CMPI stocks over time.

Checkmate Pharmaceuticals shares at a glance

• Key figures

Information last updated 2024-01-24.

52-week range	$0.00 - $0.00
50-day moving average more info button	$8.60
200-day moving average more info button	$4.78
Wall St. target price	$12.50
PE ratio more info button	N/A
Dividend yield more info button	$0 (0%)
Earnings per share (TTM) more info button	$-2.92

Is it a good time to buy Checkmate Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Checkmate Pharmaceuticals financials

Gross profit TTM	$0
Return on assets TTM	-42.31%
Return on equity TTM	-75.44%
Profit margin	0%
Book value	$2.54
Market Capitalization more info button	$231.4 million

TTM: trailing 12 months

Checkmate Pharmaceuticals share dividends

We're not expecting Checkmate Pharmaceuticals to pay a dividend over the next 12 months.

Checkmate Pharmaceuticals overview

Checkmate Pharmaceuticals, Inc. , a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. Checkmate Pharmaceuticals, Inc. has strategic alliances with Merck KGaA and Pfizer. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. As of May 27, 2022, Checkmate Pharmaceuticals, Inc.

Frequently asked questions

null
What percentage of Checkmate Pharmaceuticals is owned by insiders or institutions?
Currently 4.633% of Checkmate Pharmaceuticals shares are held by insiders and 77.512% by institutions. How many people work for Checkmate Pharmaceuticals?
Latest data suggests 30 work at Checkmate Pharmaceuticals. When does the fiscal year end for Checkmate Pharmaceuticals?
Checkmate Pharmaceuticals's fiscal year ends in December. Where is Checkmate Pharmaceuticals based?
Checkmate Pharmaceuticals's address is: 245 Main Street, Cambridge, MA, United States, 02142 What is Checkmate Pharmaceuticals's ISIN number?
Checkmate Pharmaceuticals's international securities identification number is: US1628181083